Liraglutide's Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Profile Assessed in Healthy Japanese Volunteers

The GLP-1 receptor agonist liraglutide is a well-established treatment for Type 2 Diabetes and obesity, demonstrating significant benefits in glycemic control and weight management. However, drug pharmacokinetics (PK) and pharmacodynamics (PD), as well as safety and tolerability, can vary across different ethnic populations due to genetic and environmental factors. Early-phase clinical trials are crucial to characterize these profiles in specific populations, ensuring optimal dosing strategies and identifying potential population-specific safety concerns before broader clinical application. This study specifically addresses the need for comprehensive data on liraglutide in healthy Japanese individuals.

This was a randomized, double-blind, single-center, placebo-controlled, dose-escalation study designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of liraglutide (NNC 90-1170). Healthy Japanese male subjects received multiple subcutaneous (SC) doses over a 21-day period. The study employed a dose-escalation design, with specific dose levels, such as 20 ug/kg and 25 ug/kg, being evaluated in different cohorts. Primary endpoints included the incidence of adverse events and changes in vital signs to assess safety and tolerability. Blood samples were collected at various time points for PK analysis to determine drug exposure, while PD markers were also monitored.

The abstract for this study describes its objectives as assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of liraglutide in healthy Japanese male volunteers. However, it does not present specific quantitative results regarding these parameters. Therefore, no numerical data, p-values, percentages, or fold-changes can be reported from the abstract itself. The study aimed to characterize the absorption, distribution, metabolism, and excretion of liraglutide, alongside its physiological effects, within this specific population. The primary focus was to establish a preliminary safety profile and understand how the drug behaves in healthy Japanese subjects, which is foundational for future clinical development. Without further details from the full publication, specific findings on adverse event rates, PK parameters like Cmax or AUC, or PD effects cannot be detailed.

Written by TitrateLab, separately from the study summarized above.